Alexander Gorka’s practice focuses on intellectual property litigation, prosecution, and counseling, namely in the patent space. Dr. Gorka works with a variety of clients, such as those in the life sciences industry, including the pharmaceutical and biotechnology sectors. Dr. Gorka has experience in pharmaceutical patent litigation, including ANDA litigation, domestic and foreign patent drafting and prosecution, and strategic counseling, including on issues of IP acquisition, patentability, validity, freedom to operate, and infringement.

Dr. Gorka obtained his JD degree from Fordham University School of Law. While there, he served as a teaching assistant for the legal writing program.

Prior to joining the firm in 2019, Dr. Gorka was an assistant professor in the Department of Chemistry at the University of Connecticut. While there, he led a research laboratory developing dual diagnostic/drug delivery technologies for infectious disease based on small molecule fluorophores and their bioconjugates.

From 2013 to 2017, Dr. Gorka was a postdoctoral fellow in the Chemical Biology Laboratory at the National Cancer Institute. In that role, he developed near-infrared imaging agents and light- activated drug delivery approaches for the diagnosis and treatment of cancer and for site- specific control of gene expression.

While working toward his doctorate at Georgetown University, Dr. Gorka elucidated key structure-activity principles governing drug pharmacology and resistance in malaria. He also invented multiple cell-based screening protocols for evaluating drug leads that aim to improve predictability by incorporating clinically relevant parameters.

Dr. Gorka has published 27 peer-reviewed articles, is a named inventor on a patent family and has given numerous invited lectures.

Selected Publications

  • Gorka AP, Nani RR, Schnermann MJ. Harnessing Cyanine Reactivity for Optical Imaging and Drug Delivery. Acc. Chem. Res. 2018, 51, 3226-3235.
  • Nani RR, Gorka AP, Nagaya T, Yamamoto, T, Ivanic J, et al. In Vivo Activation of Duocarmycin−Antibody Conjugates by Near-Infrared Light. ACS Cent. Sci. 2017, 3, 329-337.
  • Anderson ED, Gorka AP. Near-Infrared Uncaging or Photosensitizing Dictated by Oxygen Tension. Nat. Commun. 2016, 7, 13378.
  • Gorka AP, Nani RR, Zhu J, Mackem S, Schnermann MJ. A Near-IR Uncaging Strategy Based on Cyanine Photochemistry. J. Am. Chem. Soc. 2014, 136, 14153-14159.
  • Gorka AP, de Dios AC, Roepe PD. Quinoline Drug-Heme Interactions and Implications for Antimalarial Cytostatic versus Cytocidal Activities. J. Med. Chem. 2013, 56, 5231-5246.


  • Schnermann MJ, Nani RR, Gorka AP, Kobayashi H, inventors; The United States of America, as represented by the Secretary, Department of Health and Human Services, assignee. Near-IR Light-Cleavable Conjugates and Conjugate Precursors. US Patent No. 10,561,729; U.S. Patent No. 10,874,739; Japanese Patent No. 7042254. 


  • Fordham University School of Law Legal Writing Award (2020)
  • National Cancer Institute Cancer Research Training Award (2013-2017)
  • Federal Technology Transfer Award (2017)
  • National Cancer Institute Director’s Innovation Award (2016)
  • National Institutes of Health Fellows Award for Research Excellence (2016 and 2014)
  • Georgetown University Espenscheid Fellowship (2008)


  • Education

    • JD, Fordham University School of Law, 2023

      cum laude
    • PhD, Chemistry, Georgetown University, 2013

    • BS, Chemistry and Biochemistry, Monmouth University, 2008

      magna cum laude
  • Admissions

    • New York



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.